Pharmaceuticals Industry Trends Germany - 2022

In Germany, the progressive ageing the population will mainly benefit producers of speciality pharma products, but also manufacturers of generic drugs. Pharmaceuticals Industry Trends Germany - 2022 Robust output growth expected in 2022   [Asset Included(Id:1435221141463;Type:AT_Media_C)]   In 2020, Germany accounted for 4.5% of global pharmaceuticals production. Pharmaceuticals value added output is forecast to grow by 4% in 2022 and by more than 2% in 2023, after increasing 5.2% in 2021. Health care growth remains robust this year, expected to increase by more than 4%.     [Asset Included(Id:1435221140796;Type:AT_Media_C)]   Covid-19 vaccines have mainly driven demand, while at the same time producers of cold medicines have recorded lower sales, as physical distancing and mask wearing reduced the number of related diseases. There is still a backlog of non-Covid related medical treatments and spending on drugs. However, a rebound is underway, and non-Covid related pharmaceuticals output will benefit this year and in 2023.  Mid-and long-term demand for pharmaceuticals will be driven by demographic developments. The progressive ageing of Germany´s population will require an increase in medical treatments, in particular for chronic diseases. This will mainly benefit producers of speciality products, but also manufacturers of generic drugs. The German healthcare market is highly regulated, and the legislative pressure on pharmaceutical businesses to lower their sales prices of drugs for end-consumers is not overly high.  Profit margins of both producers and pharmacies have increased in 2021, while pharmaceutical wholesalers/distributors continue to work with low margins. With a potential abatement or even an end of the pandemic we expect profit margins of producers and pharmacies will likely flatten. In general, German pharmaceutical businesses have robust equity, solvency and liquidity. Payments take 30-60 days on average. Compared with other German industries, the sector´s payment behaviour has always been better than average, with no notable payment delays. The insolvency environment is stable, and we expect business failures to remain at a low level. Due to the benign credit risk situation of most businesses and the good growth prospects in the coming years, our underwriting stance is open for producers, wholesalers/distributors and pharmacies/drugstores. Wenst u inzicht in een visueel beknopt overzicht van de trends in de farmaceutische industrie in 13 vooraanstaande landen, alsook info over de aandrijvers voor groei en de beperkingen voor de gehele industrie in detail te bekijken? Download hier het volledige rapport